middle.news
Orthocell’s Remplir™ Study Validates Nerve Repair Breakthrough Ahead of US Launch
9:10am on Thursday 19th of June, 2025 AEST
•
Healthcare
Read Story
Orthocell’s Remplir™ Study Validates Nerve Repair Breakthrough Ahead of US Launch
9:10am on Thursday 19th of June, 2025 AEST
Key Points
Remplir™ enables earlier nerve function restoration versus suture-only repair
Study shows reduced inflammation and better nerve tissue alignment with Remplir™
Orthocell targets a US$3.5 billion total addressable market for Remplir™
Company fully funded with circa $30 million cash for global expansion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE